Changes

'''{{Construction SiteFULLPAGENAME}} HP802-247 ''' is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose [[skin ]] will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be [[skin ]] graft.<ref>{{cite webREFweb |last= |first= |date=2012-08-03 |title=Spray-on-skin' treatment for leg ulcers | url = http://www.nhs.uk/news/2012/08august/pages/spray-on-skin-treatment-for-leg-ulcers.aspx | title publisher= 'Spray-on-skin' treatment for leg ulcers NHS | accessdate = 2012-11-24 | date = 2012-08-03 | publisher = NHS}}</ref>

The new spray (HP802study was conducted by researchers from the {{UNI|University of Miami|UMiami}} and other institutions in the [[United States]] and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal ''The Lancet''.<ref>{{REFweb |last= |first= |date=201209 |title=Spray-247) consisted applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a combination of donated skin cells and proteinsphase 2, multicentre, double-blind, randomised, placebo-controlled trial |url=http://www.thelancet. com/journals/lancet/article/PIIS0140-6736(12)60644-8/abstract |publisher=The Lancet |accessdate=2012-11-24}}</ref>

The study was conducted by researchers from new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the University outer layer of Miami and other institutions in the US [[skin]], and was funded by Healthpoint Biotherapeuticsfibroblasts, a biotech company that specialises cell type found in wound care productsconnective tissue. The study was published These cells had been grown in the peer-reviewed medical journal The Lancet.<ref>{{cite web | url = http://www.thelancet.com/journals/lancet/article/PIIS0140-6736laboratory and were originally derived from newborn [[foreskin]] samples (12removed during [[circumcision]])60644-8/abstract | title = Spray-applied cell therapy with human allogeneic fibroblasts . This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and keratinocytes for to find out the best dose to use. If the treatment results of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trials are positive (as these trial | accessdate = 2012-11-24 | date = 201209 | publisher = The Lancet}}</ref>results were) they will usually be followed by larger phase 3 trials.

==References==<div class='references-small'><references/></div> [[Categoryde:Foreskin Products]][[Category:Financial Gain]][[Category:CircLeaks]] [[Category:Construction Site]][[Category:From IntactWiki{{FULLPAGENAME}}]]